Halozyme Dose Response Study Demonstrates Significant Insulin Responses Print E-mail
By Staff and Wire Reports   
Wednesday, 21 October 2009 13:01

Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced dose response study results that demonstrated faster insulin absorption and increased peak insulin concentrations after co-administration of its recombinant hyaluronidase enzyme (rHuPH20 or PH20) with regular human insulin and with insulin lispro.

The enhanced absorption effects were observed at clinically relevant insulin doses across a broad range of PH20 concentrations. In addition, study results also showed accelerated insulin action as measured by glucose infusion rates in this euglycemic glucose clamp study. The company presented these results today at the International Diabetes Federation Congress in Montreal.

"This study has demonstrated faster insulin absorption for varying insulin doses and PH20 concentrations. Even at relatively low insulin doses and low concentrations of PH20, the faster insulin absorption produced an acceleration of the effects of insulin," said Doug Muchmore, M.D., vice president, endocrinology clinical development. "This dose response study allowed us to determine the optimal enzyme concentration, an important milestone in the development of our ultrafast insulin program, which has already been useful in the design of ongoing clinical trials."




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter